Actively Recruiting
Finnish Children´s Protracted Cough
Led by Tampere University Hospital · Updated on 2026-05-13
100
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prolonged cough lasting more than four weeks is common in children, but the best treatment is often unclear when no underlying disease can be found. This study aims to find out whether commonly used treatments help children with prolonged cough more effectively than placebo. Children who take part will first undergo standard medical examinations, including lung function tests and a chest X-ray, to look for the cause of the cough. If no specific cause is found, the child may enter the study. Children with a dry cough will be randomly assigned to receive either an inhaled corticosteroid (fluticasone) or a placebo inhaler for two months. Children with a wet or productive cough will be randomly assigned to receive either an oral antibiotic (amoxicillin-clavulanic acid) or a placebo medicine for 14 days. Neither the families nor the researchers will know which treatment the child receives during the study. The main goal is to determine whether these treatments significantly reduce or stop the cough compared with placebo. The results will help improve treatment recommendations for children with prolonged cough and avoid unnecessary medication use. Participation is voluntary, and parents provide written informed consent for their child.
CONDITIONS
Official Title
Finnish Children´s Protracted Cough
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cough lasting continuously for more than 4 weeks
- Generally healthy child with no chronic disease requiring continuous medication
- No previous doctor-diagnosed condition linked to prolonged cough
- No symptoms or findings suggesting underlying disease
- No prior severe allergic or life-threatening reaction to study medications (fluticasone or amoxicillin-clavulanic acid)
- Not participating in another clinical drug trial
- Parents or guardians able to speak and write Finnish
- Written informed consent provided by parent or legal guardian
You will not qualify if you...
- Symptoms or findings suggesting an underlying cause of cough
- Previous doctor-diagnosed disease linked to prolonged cough
- Abnormal lung function test
- Abnormal chest X-ray (except allowed peribronchial markings)
- Prior severe allergic or life-threatening reaction to study medications
- Participation in another clinical drug trial
- Cough resolved spontaneously before study visit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Study Site: Tampere University Hospital (TAYS), Children's and Adolescents' Hospital Outpatient Paediatrics Unit P.O. Box 2000, FI-33521 Tampere, Finland
Tampere, Finland
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here